Background
==========

Occupying more than 90% of pancreatic cancer (PC), pancreatic adenocarcinoma (PCa) is one of the most aggressive and lethal malignancies with extremely dismal overall median survival of 6 months and 5-year survival rates of lower than 5% [@B1]. Due to the lack of early symptoms, most PCa patients were diagnosed at an advanced stage, which do not have any opportunity of surgical resection. Even in patients who undergo surgical resection, the disease commonly recurs within 12 months due to the aggressive nature [@B2]. The high resistance to chemotherapy and radiotherapy as well as the limited effectiveness of molecular targeted therapy (MTT) also contributes to exceptionally poor long-term survival [@B3]. Survival analysis of PCa patients with the advantage of providing risk stratification could be utilized to develop effective treatment modalities and improve clinical outcomes.

For the moment, survival for PCa could be indicated according to the traditional pathological characteristics of the tumor such as TNM stage, grade of differentiation, or positive resection margins [@B4]. However, inconsistence often exists between these indicators and survival [@B5]. Carbohydrate antigen 19-9 (CA19-9) is currently confirmed as the best serum marker to establish prognosis for PCa. But its low specificity brings a high number of false positives [@B6]. Additionally, up to 10% of the population cannot synthesize the antigen [@B7]. Therefore, new biomarkers so as to predict PCa progression and prognosis are essential for improving patient survival.

Long non-coding RNAs (lncRNAs) are transcripts with a length of more than 200 nucleotides without protein-coding functions [@B8]. Increasing evidences have shown that lncRNAs play important roles in regulating gene expression at the transcriptional, posttranscriptional and chromosomal levels and are associated with large range of biological processses, such as transcriptional regulation, cell growth and tumorigenesis [@B9], [@B10]. Some lncRNAs have been found to act as oncogenic or tumor suppressive roles in the development and progression of cancer [@B11]. Over the last few years, lncRNAs have been utilized as biomarkers for diagnosis and prognosis in various cancers [@B12]-[@B18]. MALAT-1, HOTAIR, and PVT-1 are some of most widely studied lncRNAs in the prognostic value of PC [@B19]-[@B23]. However, most studies focused on a limited number of lncRNAs based on small patient size. In this work, we comprehensively analyzed the data retrieved from The Cancer Genome Atlas (TCGA, <http://cancergenome.nih.gov/>) to develop a panel of lncRNA signature which might predict the outcome of PCa patients.

Methods and Materials
=====================

Expression profiles and sample information
------------------------------------------

The level 3 RNA-seq files and clinical features of 166 PC patients were retrieved from TCGA data portal. To obtain lncRNAs specific for PCa, six patients with the other types of pancreatic cancer (4 with pancreas-colloid (mucinous non-cystic) carcinoma, 1 with pancreas-undifferentiated carcinoma and 1 with inconsistent histologic type) were excluded. Thus, a total of 160 PCa patients with clinical data and without other malignancies were enrolled in our study. The corresponding clinical information including gender, age, tumor location, tumor size, grade, residual status, AJCC TNM stage, smoking status, drinking status, diabetes status, adjuvant radiotherapy, MTT status and treatment outcome of first course (most patients received gemcitabine based chemotherapy and a few patients with fluorouracil based chemotherapy) was recorded. The lncRNAs derived from TCGA were annotated by Ensemble ID from GENCODE project [@B24]. And the expressed lncRNAs were defined as those with an average reads per kilobase per million mapped reads (RPKM) ≥ 0.3 across all 160 PCa patients. Consequentially, the expression of 2300 lncRNAs was analyzed in our study. As the data were downloaded from TCGA, further approval by an ethics committee was not required. Data procession was performed in accordance with the TCGA human subject protection and data access policies.

Statistical analysis
--------------------

The expression profiles of lncRNAs were log2 transformed for further analysis. The relationship between the expression level of each lncRNA and PCa patients\' OS was evaluated by Cox regression analysis using the BRB array tools package which was developed by Richard Simon and the BRB-Array Tools Development Team [@B25]. Through 10,000 permutations, the lncRNAs with permutation P values \< 0.0001 were identified and were classified into risky (with a hazard ratio (HR) for death greater than 1) and protective (based on a HR for death less than 1) types. A risk score formula was constructed for predicting OS based on a linear combination of the expression level multiplied regression coefficient derived from the univariate cox regression model (β) [@B26], [@B27]: risk score = expgene1\*βgene1 + expgene2\*βgene2 + ...expgenen\*βgenen. Using the median risk score as the cutoff point, PCa patients were divided into high score and low score groups.

The prognostic value of clinical variables and the lncRNA risk score on OS of PCa patients were initially assessed by univariate Cox proportional hazards regression analyses. Subsequently, each variable identified via univariate analysis was evaluated by multivariate Cox proportional hazards regression analysis. Survival curves were estimated using the Kaplan- Meier methodology and compared with log-rank test.

The association of the lncRNA signature and clinical variables was evaluated by Chi-square test. The predictive value of the lncRNA risk score for patients\' outcome after first course of treatment was assessed by receiver operating characteristic (ROC) curve analysis. All the statistical analyses were conducted with BRB-Array Tools and SPSS 16.0 software (SPSS Inc., Chicago, IL, USA), as appropriate. A two-sided P value \< 0.05 was defined as statistical significance unless specifically indicated.

Functional enrichment analysis
------------------------------

Pearson correlation coefficients were computed to assess co-expressed relationships between the risky/protective lncRNAs and protein-coding genes (PCGs). The genes with correlation coefficients higher than 0.4 were identified as the co-expressed PCGs. To evaluate the potential biological processes and pathways the lncRNAs might involve in, functional enrichment analysis based on the co-expressed PCGs was performed for Gene ontology (GO) biological process (BP) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway using the DAVID Bioinformatics Tool (<https://david.ncifcrf.gov/>, version 6.8) [@B28]. The GO terms and KEGG pathways with P value \< 0.01 were considered as significantly enriched function annotations.

Gene set enrichment analysis (GSEA) was carried out to explore the potential altered pathways between the high risk score and low score group with java software GSEA (<http://software.broadinstitute>. org/gsea/index.jsp) [@B29]. False discovery rate (FDR) value \< 0.05 after 1000 random permutations was set as the cutoff criterion.

Results
=======

Characteristics of patients
---------------------------

A total of 160 patients with PCa were included in this study. The detailed clinical features of all patients were shown in Table [1](#T1){ref-type="table"}. The mean ± standard deviation (SDV) age for the patients was 64.8 ± 10.9. Among the 160 patients, 73 patients with tumor size less than 35 mm, 99 obtained R0 resection, and 28 and 77 patients received adjuvant radiotherapy and MTT, respectively. Fifty-six patients died during the follow-up (mean ± SDV: 12.8 ± 15.8 months). Moreover, 90 patients\' information on treatment outcome was available. According to the RECIST criteria, 38 (42.2%) acquired complete response (CR), 8 (8.9%) partial response (PR), 7 (7.8%) stable disease (SD) and 37 (41.1%) progressive disease (PD).

Identification of lncRNAs correlated with OS
--------------------------------------------

According to the criteria, a total of 2300 lncRNAs were initially identified as the expressed lncRNAs and were selected for further analysis on prognostic value in PCa. Twelve lncRNAs (6 protective lncRNAs: CTC-429P9.3, CTD-2186M15.3, RP5-890O3.9, AP000254.8, RP5-1085F17.3, LINC01089, and 6 risky lncRNAs: LINC00941, ABHD11-AS1, CASC8, CYTOR, MIR4435-2HG, UCA1; Supplementary Table [S1](#SM0){ref-type="supplementary-material"} online) were additionally proved to be significantly associated with OS in PCa patients.

We also analyzed the relationship between the lncRNAs and clinical characteristics (Table [2](#T2){ref-type="table"}). The results showed that the expression level of UCA1 was inversely related with patients\' age. RP5-1085F17.3 was up-regulated in no-smoking patients compared with smoking patients. The expression of three protective lncRNAs (CTD-2186M15.3, RP5-890O3.9 and AP000254.8) was higher in patients without diabetes than those with diabetes. Four lncRNAs (a risky lncRNA with positive correlation: LINC00941 and three protective lncRNAs with negative correlation: CTC-429P9.3, AP000254.8 and RP5-1085F17.3) were observed to be significantly associated with tumor grade. Four protective lncRNAs (CTC-429P9.3, CTD-2186M15.3, AP000254.8 and RP5-1085F17.3) showed lower expression level in patients with advanced stages. And four protective lncRNAs (RP5-890O3.9, AP000254.8, RP5-1085F17.3 and LINC01089) were prominently related with better treatment outcome. However, we found no significant correlation else between the lncRNAs and other clinical features.

The lncRNA signature as an independent factor to predict PCa prognosis
----------------------------------------------------------------------

The risk score for predicting OS of each PCa patients was calculated based on the expression levels and the corresponding regression coefficients of the twelve lncRNAs. The equation for the risk score of the 12-lncRNA signature was shown as: risk score = 0.108\*LINC00941 + 0.028\*ABHD11-AS1+0.198\*CASC8+ 0.149 \*CYTOR + 0.332\*MIR4435-2HG + 0.009\* UCA1 - 0.353\*CTC-429P9.3 - 0.534\*CTD- 2186M15.3 - 0.197\*RP5-890 O3.9 - 0.453\* AP000254.8 - 0.26\*RP5-1085F17.3 - 0.335\* LINC01089. According to the median risk score, 160 PCa patients were divided into two groups of low score group (n = 80) and high score group (n = 80). As shown in Figure [1](#F1){ref-type="fig"}A, higher expression was observed for the protective lncRNAs in low score group, while in high score group higher expression was noted for the risky lncRNAs. Compared with the low score group, the patients in the high score group exhibited obviously worse OS (Figure [1](#F1){ref-type="fig"}B). Analyses on the relationship between the risk score and clinical features demonstrated that higher risk score was remarkably associated with later stages and worse treatment outcome (Table [2](#T2){ref-type="table"}).

The univariate Cox regression analyses were performed to evaluate various factors correlated with patients\' prognosis. The results showed that tumor size (P = 0.037), tumor grade (P = 0.001), residual tumor (P = 0.006), TNM stage (P \< 0.001), adjuvant radiotherapy (P = 0.006), MTT (P = 0.002), treatment outcome of the first course (P = 0.001) and risk score (P \< 0.001) were significantly associated with PCa patients\' OS. Subsequently, multivariate Cox regression analyses suggested that tumor grade (P = 0.002), TNM stage (P = 0.033), MTT (P \< 0.001) and risk score (P = 0.002) were independent prognostic indictors (Table [3](#T3){ref-type="table"}).

The lncRNA signature risk score as an indicator to predict treatment outcome
----------------------------------------------------------------------------

Kaplan-Meier curves showed that the 53 PCa patients who acquired disease control (DC: CR + PR + SD) after treatment of first course had better OS than the 37 patients with PD (Figure [2](#F2){ref-type="fig"}A). To confirm whether the risk score has the power to predict treatment outcome of first course, the difference of risk score in the two groups (DC VS. PD) was compared. And the ability of risk score in distinguishing the two groups was evaluated with ROC curves. As shown in Figure [2](#F2){ref-type="fig"}B, risk score of PCa patients in DC group was markedly lower than those in PD group. The area under the curve (AUC) was 0.658 (95% confidence interval (CI): 0.545 - 0.772). The optimal cutoff value to predict treatment outcome was set at -3.38. Using this threshold, the risk score achieved a sensitivity of 72.9% and a specificity of 58.5%.

The 49 PCa patients with risk score higher than the cutoff value suffered worse OS than the 41 cases with lower score (Figure [2](#F2){ref-type="fig"}D). To confirm the prognostic power of the 12 lncRNA signature for survival, the other 70 patients without information of treatment outcome were divided into a high score group (n = 26) and a low score group (n = 44) with the same cutoff value. As shown in Figure [2](#F2){ref-type="fig"}E, the patients in high score group suffered shorter survival than patients in low score group with borderline significance (P = 0.108). Similar results were found when the 12 lncRNA signature was further applied to the entire dataset. Based on the cutoff value, the low score group (n = 85) exhibited longer survival, whereas the high score group exhibited shorter survival (n = 75; Figure [2](#F2){ref-type="fig"}F).

Assessment of the biological processes and pathways related with the 12-lncRNA signature
----------------------------------------------------------------------------------------

To evaluate the potential biological processes and pathways the identified lncRNAs might involve in, GO and KEGG functional enrichment analyses based on co-expressed PCGs were conducted for the risky and protective lncRNAs, respectively. The results showed that co-expressed PCGs of the risky lncRNAs were enriched in 629 GO BP terms including mitotic cell cycle process, DNA metabolic process, positive regulation of ubiquitin protein ligase activity and so on. The protective lncRNAs might also play important roles in 66 GO BP terms (Supplementary Table [S2](#SM0){ref-type="supplementary-material"} online; Figure [3](#F3){ref-type="fig"}A: the top 10 GO BP terms for the risky and protective lncRNAs, respectively). Fifteen and one KEGG pathways for the risky and protective lncRNAs were enriched, respectively. Among them, the risky lncRNAs related pathways such as proteasome, cell cycle, DNA replication, regulation of actin cytoskeleton and PC were more closely related with PCa (Figure [3](#F3){ref-type="fig"}B). In addition, GSEA was performed according to the risk score of the 12-lncRNA signature. And a total of 304 biological processes or pathways were identified (Supplementary Table [S2](#SM0){ref-type="supplementary-material"} online). Among these pathways, cyclin binding and regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling might be associated with cell proliferation; cadherin binding, fibronectin binding and gap junction might play important roles in migration of cancer cells; histone kinase activity, regulation of tor signaling and kras dependency signature should be noted for their roles in carcinogenesis and cancer maintenance (Figure [4](#F4){ref-type="fig"}; Supplementary Table [S3](#SM0){ref-type="supplementary-material"} online).

Discussion
==========

PCa is the main types of PC and remains one of the most lethal of malignancies with extremely poor prognosis all around the world. Over the past decades, efforts in clinical treatment did not satisfactorily improved survival time [@B1]. It is of great urgency to develop an optimized individualized therapeutic approach for PCa. Specific prognostic indicators may identify subsets of patients and are more powerful when used to help make therapeutic decisions [@B30].

Recent studies highlighted the important roles of lncRNAs in PC prognosis. Overexpression of MALAT1 was reported as an unfavorable prognostic biomarker for PC patients in several studies [@B19]-[@B21]. Kim et al. showed that HOTAIR was a negative prognostic factor for PC patients [@B22]. Another study reported that increased expression of PVT1 was associated with poor prognosis in PC patients [@B23]. TCGA, a database with large-scale genomic analyses, has the power to evaluate the molecular features associated with cancer outcomes [@B31], [@B32]. In the previous study, we have identified a 13-miRNA signature which could predict prognosis in PC using the database [@B33]. To better understand molecular markers of PCa, we comprehensively analyzed the database and identified lncRNAs which could predict OS in the main types of PC patients. This is the first study to identify a panel of lncRNAs signature based on TCGA data for the survival analysis of PCa patients. To reduce heterogeneity, patients with other types of PC were not enrolled in the study. Using careful exclusion criteria, a total of 160 PCa patients with 2300 lncRNAs were selected for further evaluation. Through 10,000 permutations with P values \< 0.0001, 12 lncRNAs (6 protective and 6 risky lncRNAs) significantly related to OS were identified. The relationship between the 12 lncRNAs and clinical features was also analyzed. LINC00941, CTC-429P9.3, CTD-2186M15.3, AP000254.8 and RP5-1085F17.3 might be more closely related with PCa itself. Besides AP000254.8 and RP5-1085F17.3, RP5- 890O3.9 and LINC01089 might also play important roles in treatment of the disease. A panel of lncRNAs is more sensitive and specific than a single lncRNA. Thus, we constructed a risk score with the 12 lncRNAs. The risk score was proved to be an independent prognostic indicator for OS in PCa patients. Moreover, the risk score could also serve as a predictor for treatment outcome of first course. The prognostic power of the risk score for treatment outcome was further validated in patients without information of treatment outcome. By applying the same cutoff value, relatively less cases (26/70) were divided into the high score group. Meanwhile, few patients (10/70) reached the end- point might (due to relatively short follow-up: 9.2 ± 16.8 months; the 90 cases with information of treatment outcome: 15.5 ± 14.4) affect the statistical significance. However, the lncRNA signature could also act as a prognostic indicator with borderline significance which could also validate our findings to some extent. While extend to the whole cohort, the signature could exactly predict OS of 160 PCa patients with the cutoff value induced from the treatment outcome. These findings further confirmed our results.

Among the 12 lncRNAs, UCA1 has been demonstrated to be correlated with PC. It has been reported to function as an oncogene in multiple types of cancers [@B34]-[@B36]. Moreover, numerous studies have demonstrated that overexpression of UCA1 is an unfavorable prognostic indicator in cancer patients, including the cases with PC [@B37]-[@B39]. Chen et al. recently found that the expression of UCA1 in 128 PC tissue specimens was significantly higher than their matched adjacent non-tumor tissues. High UCA1 expression was an independent predictor of poor survival in PC. Besides, up-regulation of UCA1 was significantly correlated with malignant factors such as tumor size, depth of invasion, CA19-9 level and tumor stage [@B40]. Fu et al. analyzed the lncRNA expression profiles in GEO and identified 34 dysregulated lncRNAs in pancreatic ductal adenocarcinoma (PDAC). In addition, UCA1 was found to be involved in PDAC progression and could serve as an independent prognostic biomarker for OS of PDAC [@B41]. In our study, the prognostic value of UCA1 was in concordance with recent reports. However, UCA1 expression was only found to be associated with age, its relationship with other clinicopathological features did not show any significance. No study has evaluated the role of the other 11 lncRNAs in PC so far. But some lncRNAs have been reported to be involved in other types of cancers. Recently, Zhang et al. identified a 4-lncRNA signature (SPRY4-IT1, LINC00941, GPR158-AS1 and KCNK15-AS1) displaying prognostic values for lung adenocarcinoma (LUAD) based on TCGA dataset. Among the 4 lncRNAs, LINC00941 with higher expression was associated with longer survival [@B42]. The findings were not consistent with our results that LINC00941 acted as an indicator of worse prognosis in PCa. Chen et al. showed that ABHD11-AS1 played oncogenic roles in the development and progression of bladder cancer [@B43]. Another study reported that ABHD11-AS1 was up-regulated in gastric cancer (GC) tissues and also significantly related with clinical features [@B44]. Grembergen et al. suggested that CYTOR could indicate poor relapse-free survival of breast cancer patients, regulate genes involved in the EGFR/ mammalian target of rapamycin pathway and was required for cell proliferation, cell migration, and cytoskeleton organization [@B45]. MIR4435-2HG was reported to be related to cell-cycle in lung cancer cells and up-regulated in GC tissue and plasma samples [@B46]. A recent study showed that LINC01089 might represent a new class of EGF-controlled and ERK-mediated inhibitors of breast cancer metastasis, functioning as a tumor-suppressor lncRNA [@B47]. These results were in concordance with our study. As for the other 6 lncRNAs, no study has explored their roles to date and further researches are warranted. In the present study, we conducted GO and KEGG analyses based on co-expressed PCGs and found some molecular pathways might be closely related with PCa such as cell cycle, DNA replication and pancreatic cancer. The results of GSEA showed that the 12-lncRNA signature might play important roles in proliferation and migration of cancer cells, thus leading to maintenance of cancer and carcinogenesis. The significantly positive relationship of tumor stage and the risk score might support the findings. However, whether these lncRNAs play exactly important roles in the development and progression of PCa remains to be further investigated.

Some limitations of the study should be addressed. First, to reduce heterogeneity, patients with other types of PC were excluded. Thus, a total of 160 PCa patients were enrolled in our study. The mean time of follow-up for the whole cohort, patients with information of treatment outcome and those without was 12.8, 15.5 and 9.2 months, respectively. The research included more patients with longer follow-up time is warranted to confirm our findings in the future. Second, among the 12 lncRNAs, some lncRNAs were closely related with specific features (e.g. LINC00941, CTC-429P9.3, AP000254.8 and RP5-1085F17.3 to tumor grade; RP5-890O3.9, AP000254.8, RP5-1085F17.3 and LINC01089 to treatment outcome). In the study, we focused on the relationship of 12-lncRNA signature and OS, thus not further assessed the combination of some lncRNAs in indicating specific features of PCa. Third, the exact roles and mechanisms of the identified lncRNAs in the development, progression and treatment of PCa were not assessed with *in vitro*/*vivo* experiment and needed to be further studied.

Conclusions
===========

In summary, we assessed the genome-wide lncRNA expression profiles with 160 cases of PCa patients from TCGA, and constructed a 12-lncRNA signature, which could be served as a predictor for treatment outcome and an independent prognostic indicator for PCa. Our study could also complement clinical and pathological parameters in the effort to further understand the mechanisms of PCa.
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![The relationship between the lncRNA signature risk score and treatment outcome. (A): 53 PCa patients who acquired DC after treatment of first course suffered better OS than the 37 patients with PD. (B) risk score of PCa patients in DC group was lower than those in PD group. (C) ROC curve analysis of the risk score to discriminate patients with DC from those with PD. (D) 49 PCa patients with risk score higher than the cutoff value exhibited worse OS than the 41 cases lower than the score. (E) Kaplan-Meier curve for patients without information of treatment outcome. (F) Kaplan-Meier curve for the 160 patients form the entire dataset with the same cutoff value. DC: disease control; PD: progressive disease; OS: overall survival; ROC: receiver-operating characteristic.](jcav10p1550g002){#F2}
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###### 

Characteristics of 160 PCa patients in the study.

  Characteristics             Number
  --------------------------- --------
  **All**                     160
  **Gender**                  
  male                        88
  female                      72
  **Age (year)**              
  \<65                        74
  ≥65                         86
  **Location**                
  head                        126
  body                        11
  tail                        12
  others                      11
  **Size (mm)**               
  \<35                        73
  ≥35                         82
  NA                          5
  **Grade**                   
  G1                          29
  G2                          83
  G3                          47
  G4                          1
  **Residual tumor**          
  R0                          99
  R1                          49
  R2                          2
  RX                          4
  NA                          6
  **TNM stage**               
  IA                          6
  IB                          13
  IIA                         23
  IIB                         111
  III                         3
  IV                          3
  NA                          1
  **Smoker**                  
  No                          56
  Yes                         74
  NA                          30
  **Drinker**                 
  No                          27
  Yes                         62
  NA                          71
  **Diabetes**                
  No                          97
  Yes                         34
  NA                          29
  **Adjuvant radiotherapy**   
  No                          90
  Yes                         28
  NA                          42
  **MTT**                     
  No                          43
  Yes                         77
  NA                          40

MTT: molecular targeted therapy; NA: not available.

###### 

Correlations of the 12 lncRNAs and the lncRNA signature risk score with clinical features in PCa patients (presented as P value).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ID              Gender (female VS. male)   Age (\<65 VS. ≥65)   Grade (G1+G2 VS. G3+G4)   Tumor size (\<35 mm VS. ≥35 mm)   Stage (I vs. II Vs. III+IV)   Smoking (smoker VS. non-smoker)   Drinking (drinker VS. non-drinker)   Diabetes\      Location\                  Treatment outcome\
                                                                                                                                                                                                                                   (yes VS. no)   (head VS. body VS. tail)   (DC VS. PD)
  --------------- -------------------------- -------------------- ------------------------- --------------------------------- ----------------------------- --------------------------------- ------------------------------------ -------------- -------------------------- --------------------
  LINC00941       0.358                      0.795                0.009                     0.329                             0.267                         0.686                             0.509                                0.321          0.751                      0.356

  ABHD11-AS1      0.495                      0.303                0.472                     0.402                             0.193                         0.665                             0.363                                0.291          0.306                      0.188

  CASC8           0.964                      0.771                0.195                     0.572                             0.492                         0.263                             0.844                                0.475          0.551                      0.925

  CYTOR           0.373                      0.24                 0.644                     0.864                             0.884                         0.377                             0.407                                0.416          0.945                      0.673

  MIR4435-2HG     0.97                       0.454                0.693                     0.246                             0.735                         0.595                             0.437                                0.908          0.975                      0.331

  UCA1            0.967                      **0.04**             0.092                     0.9                               0.25                          0.814                             0.52                                 0.557          0.584                      0.331

  CTC-429P9.3     0.781                      0.748                **0.019**                 0.06                              **0.003**                     0.269                             0.175                                0.358          0.645                      0.058

  CTD-2186M15.3   0.262                      0.152                0.726                     0.17                              **0.018**                     0.337                             0.272                                **0.011**      0.921                      0.058

  RP5-890O3.9     0.3                        0.235                0.864                     0.634                             0.316                         0.686                             0.459                                **0.047**      0.277                      **0.027**

  AP000254.8      0.845                      0.997                **0.018**                 0.168                             **0.023**                     0.17                              0.481                                **0.016**      0.98                       **0.002**

  RP5-1085F17.3   0.693                      0.782                **0.008**                 0.26                              **\<0.001**                   **0.013**                         0.701                                0.208          0.35                       **0.014**

  LINC01089       0.146                      0.735                0.652                     0.14                              **0.101**                     0.843                             0.218                                0.737          0.201                      **0.007**

  Risk score      1                          0.899                0.154                     0.076                             **0.039**                     0.696                             0.52                                 0.211          0.975                      **0.011**
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DC: disease control; PD: progressive disease.

###### 

Cox proportional regression analysis for assessing the correlation of clinical factors and the lncRNA signature risk score with OS in PCa patients.

  Variables                                              Univariate analysis                  Multivariate analysis                          
  ------------------------------------------------------ ---------------------- ------------- ----------------------- ---------------------- -------------
  Gender (female VS. male)                               0.79 (0.462, 1.353)    0.391                                                        
  Age (≥65 VS. \<65)                                     1.493 (0.876, 2.546)   0.141                                                        
  Location (tail VS. body VS. head)                      0.582 (0.335, 1.014)   0.056                                                        
  Size (≥35 VS. \<35; mm)                                1.799 (1.035, 3.124)   **0.037**                             0.846 (0.426, 1.679)   0.633
  Grade (G4 vs. G3 VS. G2 VS. G1)                        1.808 (1.269, 2.575)   **0.001**                             1.89 (1.255, 2.846)    **0.002**
  Residual tumor (yes Vs. no)                            2.217 (1.262, 3.896)   **0.006**                             1.308 (0.648, 2.64)    0.453
  TNM stage (IV VS. III VS. IIB VS. IIA VS. IB VS. IA)   1.764 (1.267, 2.455)   **\<0.001**                           1.606 (1.037,2.487)    **0.033**
  Smoking (smoker VS. non-smoker)                        1.201 (0.699, 2.066)   0.507                                                        
  Alcohol (drinker VS. none)                             0.632 (0.295, 1.353)   0.238                                                        
  Diabetes (yes VS. no)                                  0.992 (0.509, 1.933)   0.981                                                        
  Adjuvant radiotherapy (yes VS. no)                     0.33 (0.149, 0.733)    **0.006**                             0.853 (0.304, 2.389)   0.762
  Molecular targeted therapy (yes VS. no)                0.428 (0.249, 0.735)   **0.002**                             0.203 (0.091, 0.454)   **\<0.001**
  Treatment outcome (PD VS. DC)                          2.731 (1.489, 5.009)   **0.001**                             1.308 (0.67, 2.552)    0.432
  Risk score (high VS. low)                              3.732 (2.075, 6.714)   **\<0.001**                           3.561 (1.58, 8.024)    **0.002**

HR: hazard ratio; CI: confidence interval; DC: disease control; PD: progressive disease.
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